Pacira Data Suggests EXPAREL Drives Cost Savings in Outpatient Arthroplasty
Event summary
- Pacira BioSciences presented three real-world studies at the AMCP Annual 2026 Meeting demonstrating lower total healthcare costs associated with EXPAREL use in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) procedures.
- One study found lower healthcare costs (3-month: $7,332 vs $8,153; 6-month: $13,022 vs $15,081) and reduced opioid utilization in Medicare Advantage beneficiaries undergoing THA with EXPAREL.
- A three-year budget impact analysis projected cumulative cost savings of $117,868 per 1 million members by year 3 compared to ropivacaine in Commercial and Medicare Advantage settings.
- In teaching hospitals, EXPAREL use was associated with lower adjusted costs at all evaluated time points, with pharmacy costs significantly lower on the day of surgery.
The big picture
Pacira's data reinforces the growing trend towards value-based care and opioid-sparing pain management solutions within the orthopedic surgery space. The findings suggest EXPAREL can offer a compelling economic argument for payers seeking to reduce overall healthcare expenditures while addressing the opioid crisis. The $117,868 projected savings, while dependent on model assumptions, represents a potentially significant opportunity for Pacira to expand its market share and solidify its position as a leader in non-opioid pain therapies.
What we're watching
- Market Adoption
- The pace at which these cost savings findings translate into broader adoption of EXPAREL within hospital outpatient departments will depend on payer coverage decisions and physician acceptance.
- Competitive Response
- Ropivacaine manufacturers and other pain management solution providers will likely attempt to counter Pacira’s claims and highlight any limitations in the presented data.
- Regulatory Scrutiny
- Continued emphasis on opioid stewardship may lead to increased regulatory scrutiny of EXPAREL's use and require Pacira to proactively address any concerns regarding long-term patient outcomes.
Related topics